Can I Take Creatine with Reclast (Zoledronic Acid)?

Zoledronic acid, sold under the brand name Reclast, is an intravenous bisphosphonate FDA-approved for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease, given as a single 5 mg infusion once a year (or once every two years for prevention). Creatine monohydrate is an over-the-counter dietary supplement, most often taken at 3 to 5 g per day for muscle mass, strength, or sarcopenia prevention.

There is no documented pharmacokinetic or pharmacodynamic interaction between creatine and zoledronic acid. The two do not share metabolic enzymes, transporters, or receptor targets. The real issue is analytical, not pharmacological: creatine supplementation raises serum creatinine, and zoledronic acid dosing depends on a creatinine-based estimate of kidney function. Because Reclast is contraindicated below a creatinine clearance of 35 mL/min, a creatine-driven bump in serum creatinine can make a patient's kidney function look worse than it is, and that alone can delay or cancel an infusion. This is the finding worth remembering: the drug interaction risk is essentially zero, but the lab interference risk is real and clinically meaningful, especially in older adults who already have reduced renal reserve.

What Reclast Requires From the Kidneys

Zoledronic acid is not metabolized by the liver. It circulates largely unbound, binds avidly to hydroxyapatite in bone, and the unbound fraction is cleared by the kidneys. Because of this renal elimination pathway, the FDA-approved prescribing information requires clinicians to check kidney function before each dose, and it carries a contraindication for use when creatinine clearance is below 35 mL/min. Regulatory safety communications have also described post-marketing reports of acute kidney injury after zoledronic acid infusion, most occurring in patients who had pre-existing kidney impairment, were dehydrated, or were taking other nephrotoxic drugs at the same time.

Large randomized trials of yearly zoledronic acid in postmenopausal osteoporosis (the HORIZON program) and its multi-year extension have described renal function changes as generally transient, with a small rise in creatinine after infusion that trends back toward baseline over the following one to two weeks. The exact numbers reported for onset and resolution vary between the pivotal trial and its extension study, and a reader who needs the precise figures for clinical decision-making should confirm them against the current primary publications rather than relying on a secondhand summary.

Why Creatine Raises Creatinine Without Harming the Kidneys

Creatine taken up by muscle is broken down to creatinine at a fairly constant, low rate as a normal byproduct of energy metabolism. Supplementing with additional creatine increases the amount of creatine circulating and stored in muscle, which increases the amount of creatinine produced and excreted. Reviews of creatine research commonly describe a modest rise in serum creatinine with regular supplementation, though the exact magnitude reported varies across studies by dose, duration, muscle mass, and assay method. Figures in the range of a few tenths of a mg/dL are often cited in secondary sources, but a specific number should not be treated as a fixed rule for any individual patient, and the primary studies behind any such figure should be checked before it is used in clinical counseling.

This rise reflects increased substrate turnover, not glomerular injury. Systematic reviews of creatine supplementation in healthy adults have generally not found evidence that standard doses (3 to 5 g per day) impair measured kidney function. That reassurance applies to people with normal baseline renal function; it does not establish that creatine is neutral in people who already have reduced kidney function or who are on drugs, like zoledronic acid, whose dosing decisions hinge on a creatinine-based estimate.

The GFR estimation problem

Standard estimated GFR formulas (CKD-EPI, MDRD) use serum creatinine as their main input. When creatinine rises because of exogenous creatine rather than nephron loss, these formulas will underestimate true kidney function. A patient whose actual GFR is comfortably above the Reclast cutoff could appear to fall below it on a lab report obtained while taking creatine. This is a measurement artifact, not evidence of kidney damage, but it can still trigger a deferred infusion or an unnecessary nephrology referral.

Is there a direct drug-supplement interaction?

No. Zoledronic acid inhibits farnesyl pyrophosphate synthase in osteoclasts to suppress bone resorption. Creatine replenishes phosphocreatine stores used for short-duration energy production in muscle and brain. These are unrelated mechanisms with no shared enzyme, transporter, or receptor. Zoledronic acid is not metabolized through cytochrome P450 pathways, so creatine's effect (or lack of effect) on those pathways is not relevant here. General drug-interaction references do not list creatine as an interactant with zoledronic acid; the documented concern in clinical practice is the creatinine lab artifact described above, not a pharmacologic interaction.

Evidence-status interaction assessment

Practical steps if you take both

Tell your prescriber. Both the clinician managing your osteoporosis treatment and your primary care physician should know you take creatine, listed alongside your other medications and supplements.

Time a washout before labs. Because creatine's effect on creatinine depends on how long you have been supplementing and does not disappear immediately, stopping creatine several weeks before a scheduled pre-infusion blood draw gives your creatinine time to return toward your supplement-free baseline. Ask your prescriber or pharmacist what washout interval they want to use, since a specific number of weeks should come from your clinician rather than a generic online timeline.

Ask about cystatin C if your eGFR is borderline. Cystatin C is a kidney filtration marker that is not driven by muscle creatine turnover the way serum creatinine is. KDIGO guidance recognizes cystatin C-based or combined creatinine-cystatin C equations as a way to clarify kidney function when creatinine-based estimates may be unreliable. If your creatinine-based eGFR comes back close to the 35 mL/min cutoff while you are using creatine, ask whether a cystatin C level should be checked before the infusion is deferred.

Prioritize hydration around the infusion. The Reclast label recommends that patients be adequately hydrated before administration; dehydration is one of the risk factors called out in FDA's post-marketing safety review of kidney injury after zoledronic acid. This is a general infusion-safety measure, not specific to creatine users, but it is worth confirming with the infusion center.

Hold creatine through the post-infusion follow-up lab if one is planned. If your care team checks creatinine again shortly after the infusion to assess renal response, resuming creatine before that draw will again confound the result.

Who should probably avoid the combination

Some situations shift the risk-benefit balance enough that avoiding creatine while on zoledronic acid is the more cautious choice:

• Baseline creatinine clearance already close to the 35 mL/min contraindication cutoff, leaving little margin for a lab-value shift
• Chronic kidney disease stage 3b or beyond
• Concurrent use of other nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast, high-dose vancomycin), which independently raises renal risk around the infusion and removes the safety margin

None of these situations reflect a proven harm from creatine itself. They reflect a judgment that the analytical interference and the narrow renal window around zoledronic acid dosing make the supplement not worth the complication risk for that patient.

What is established, what is not

Established: zoledronic acid's renal clearance and contraindication threshold come directly from FDA labeling. Established: creatine and zoledronic acid share no known metabolic or receptor-level interaction. Established, at a general level: creatine supplementation raises serum creatinine through increased metabolic turnover rather than kidney damage in people with normal renal function, based on the broader creatine safety literature. Not established: the exact size and duration of that creatinine rise for a given dose, and how often it actually causes a bisphosphonate infusion to be deferred in practice. Not established: any effect of creatine, positive or negative, on kidney function in patients who already have reduced renal function or CKD. Readers and clinicians should treat specific numeric claims about creatinine change, trial sizes, or fracture-risk comparisons as needing confirmation from the primary literature before they are used to counsel an individual patient.

If you experience decreased urine output, new swelling, flank pain, or symptoms of an allergic reaction after a zoledronic acid infusion, seek prompt medical evaluation rather than waiting for a scheduled follow-up.